In a report released today, Matthew O’Brien from Piper Sandler maintained a Buy rating on Tandem Diabetes Care (TNDM – Research Report), with a price target of $36.00. The company’s shares ...
For years, people with diabetes have used continuous glucose ... Once the applicator sticks to the skin, it gets to work and a tiny sensor tracks glucose levels in real time.
In a report released today, Mathew Blackman from Stifel Nicolaus maintained a Buy rating on Tandem Diabetes Care (TNDM – Research Report), with a price target of $60.00. The company’s shares ...